The short-course administration of LtxA should reduce the risk of severe immunosuppression as reported with the clinical use of Efalizumab, a monoclonal antibody against the CD11a subunit of LFA-1 for treatment of psoriasis [38]. Here, ITGAL is linked to psoriasis.